Subscribe to Newsletter

Rachel Haurwitz

The Power List 2020 – Advanced Medicine

Chief Executive Officer at Caribou Biosciences

Haurwitz has a research background in CRISPR-Cas biology and holds several patents covering CRISPR-derived technologies. She co-founded Caribou in 2012 and Intellia Therapeutics in 2014, both of which are developing genome editing therapies. Late in 2019, Caribou published a paper showing that their type I CRISPR-Cas platform, FokI-Cascade, can be used to perform genome editing with high precision.

Part of the Power List 2020

The Power List 2020

Celebrating the great minds that bring us innovation in small molecules, biopharmaceuticals, and advanced medicine.

Go to The Power List 2020

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine